Intralymphatic chemotherapy drug carriers
US8088412B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 30, 2009 |
| Grant date | Jan 3, 2012 |
| Priority date | — |
| Expiry date | Aug 29, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0019
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A chemotherapeutic composition can be configured for subcutaneous administration for preferential intralymphatic accumulation while also providing a therapeutic systemic concentration that is not toxic. The composition can include a pharmaceutically acceptable carrier, and a nanoconjugate configured for preferential intralymphatic accumulation after subcutaneous administration. The nanoconjugate can include a nanocarrier configured for preferential intralymphatic accumulation after subcutaneous or interstitial administration, and a plurality of chemotherapeutic agents coupled to the nanocarrier. The nanoconjugate can have a dimension of about 10 nm to about 50 nm. Also, the nanoconjugate can be loaded with the chemotherapeutic agents from about 10% to about 50% w/w. The nanocarrier can be a hyaluronan polymer of about 3 kDa to about 50 kDa. Alternatively, the nanocarrier can be a dendrimer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.